BPC-157 — the most-searched peptide.

BPC-157 is a stable fragment of a larger protein the body produces to protect and repair the gastrointestinal tract. The working clinical hypothesis is that supplemental BPC-157 extends those repair signals to other tissues — tendons, ligaments, muscle, and the gut barrier itself.

The strongest evidence base is in animal models (tendon repair, gastric ulcer healing, NSAID-induced injury). Human clinical trial data is thinner but growing; anecdotal patient reports are consistent and align with the mechanism.

BPC-157 appears to work through several pathways:

• Upregulation of vascular endothelial growth factor (VEGF) — drives new blood vessel formation at injury sites
• Modulation of the nitric-oxide system
• Direct support of growth-hormone signaling
• Possible direct effect on tendon fibroblast migration

It's not a single-pathway drug. It's a tissue-repair signal that affects multiple downstream systems simultaneously.

BPC-157 makes clinical sense for:

• Soft-tissue injury recovery (tendons, ligaments, muscle)
• Post-surgical healing (often paired with TB-500)
• Gut barrier and IBD-adjacent issues
• NSAID-induced gastric irritation
• Training overload — common request among lifters/CrossFit-culture patients

Important caveat: patients with active or history of cancer should approach BPC-157 cautiously. The VEGF mechanism that drives tissue repair could theoretically support tumor angiogenesis. Discuss with your physician.

Typical clinical protocols: 250–500mcg subcutaneous injection, once or twice daily, for 4–8 weeks (cycled, not continuous). Higher doses for tendon repair; lower for gut protocols.

BPC-157 is often paired with TB-500 (Thymosin Beta-4) for systemic effect — a common stack for post-injury or training- block recovery.

Patients with soft-tissue injuries typically report inflammation reduction within the first 1–2 weeks and functional improvement by weeks 3–4. Full tendon-repair cycles typically run 4–8 weeks; gut-focused protocols are often shorter (2–4 weeks) at slightly higher dose.

We re-assess at the end of each cycle. Patients who need continued support typically take 2–4 weeks off between cycles rather than running continuously.

Vektor prescribes BPC-157 through our U.S. 503A pharmacy partner — standard format is 3mg/mL in a 5mL vial. We do not source from gray-market “research peptide” resellers, and we don't prescribe BPC-157 without a documented clinical indication.

Patients with cancer history are screened individually. The VEGF-mechanism conversation happens up-front, not buried in fine print. Compounded availability depends on current FDA 503A regulatory posture; your physician walks through what's available at the time of your protocol design.